ASX: RMD - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Brookfield completes $3bn Oaktree buyout as credit platform reaches $365 bn

Williams to buy Momentum Midstream for $5.5bn as Haynesville LNG strategy accelerates

Snap revenue jumps 19% as AI advertising tools revive $SNAP investor confidence

Control Bionics (ASX: CBL) registers NeuroStrip with US FDA as commercial execution becomes the next test

Visual comparison of top ASX-listed medtech companies in 2025—Cardiex, ResMed, ImpediMed, and Volpara—highlighting their innovation focus, AI integration, and stock momentum.

Read More

Healthcare Industry News

How Cardiex, ResMed, ImpediMed, and Volpara are shaping Australia’s MedTech future in 2025

Comparing Cardiex, ResMed, ImpediMed, and Volpara in 2025 to see which ASX medtech firm is best positioned for growth in diagnostics, AI, and digital health.

byPallavi Madhiraju

June 2, 2025

web analytics